Investor Relations Investor Center Stock Information Financial Information Corporate Governance Press Releases Events & Presentations Investor FAQ Contact Us
Press Releases Year: - Any -202420232022202120202019201820172016201520142013201220112010200920082007 Summary ToggleTekmira Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference and the Stifel Nicolaus Healthcare Conference Sep 09, 2010 Tekmira Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference and the Stifel Nicolaus Healthcare Conference 13.7 KB ... Read more Summary ToggleTekmira Pharmaceuticals Strengthens Management Team with Addition of Paul Brennan as Senior Vice President, Business Development Sep 08, 2010 Tekmira Pharmaceuticals Strengthens Management Team with Addition of Paul Brennan as Senior Vice President, Business Development 17.8 KB ... Read more Summary ToggleTekmira Pharmaceuticals Receives Clearance from FDA to Initiate TKM-PLK1 Phase 1 Clinical Trial Sep 07, 2010 Tekmira Pharmaceuticals Receives Clearance from FDA to Initiate TKM-PLK1 Phase 1 Clinical Trial 18.5 KB ... Read more Summary ToggleTekmira Pharmaceuticals Announces Second Quarter 2010 Financial Results Aug 12, 2010 Tekmira Pharmaceuticals Announces Second Quarter 2010 Financial Results 30.4 KB ... Read more Summary ToggleTekmira Pharmaceuticals Conference Call Advisory Second Quarter 2010 Operating Results and Corporate Update Aug 10, 2010 ... Read more Summary ToggleTekmira Pharmaceuticals Files IND Application with U.S. FDA for PLK1 SNALP Aug 05, 2010 Tekmira Pharmaceuticals Files IND Application with U.S. FDA for PLK1 SNALP 18 KB Clinical Trial for RNAi Cancer Program on Track to Commence in Second Half of 2010 ... Read more Summary ToggleTekmira Awarded up to $140 Million U.S. Government Contract to Develop RNAi Therapeutic Against Ebola Virus Jul 15, 2010 Tekmira Awarded up to $140 Million U.S. Government Contract to Develop RNAi Therapeutic Against Ebola Virus 20.3 KB ... Read more Summary ToggleTekmira’s Partner Alnylam Initiates Dosing in a Phase 1 Clinical Trial of ALN-TTR01 Jul 07, 2010 Tekmira’s Partner Alnylam Initiates Dosing in a Phase 1 Clinical Trial of ALN-TTR01 19.9 KB -ALN-TTR01 Utilizes Tekmira’s Leading SNALP Delivery Technology- ... Read more Summary ToggleTekmira Partner Alnylam Presents ALN-VSP Preliminary Phase 1 Clinical Trial Results at American Society of Clinical Oncology (ASCO) Annual Meeting Jun 07, 2010 Tekmira Partner Alnylam Presents ALN-VSP Preliminary Phase 1 Clinical Trial Results at American Society of Clinical Oncology (ASCO) Annual Meeting 18.8 KB ... Read more Summary ToggleTekmira Reports Complete Protection from Deadly Ebola Virus in Nonhuman Primates with SNALP-RNAi May 28, 2010 Tekmira Reports Complete Protection from Deadly Ebola Virus in Nonhuman Primates with SNALP-RNAi 22.2 KB <ul><li>Data Reflects High Potency and Utility of RNAi in Infectious Disease Applications</li></ul> ... Read more Pagination First page First Previous page Previous … Page 43 Current page 44 Page 45 Page 46 … Next page Next Last page Last Shareholder Tools Email Alerts Email Alerts RSS News Feeds RSS News Feeds Download Library Download Library
Press Releases Year: - Any -202420232022202120202019201820172016201520142013201220112010200920082007 Summary ToggleTekmira Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference and the Stifel Nicolaus Healthcare Conference Sep 09, 2010 Tekmira Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference and the Stifel Nicolaus Healthcare Conference 13.7 KB ... Read more Summary ToggleTekmira Pharmaceuticals Strengthens Management Team with Addition of Paul Brennan as Senior Vice President, Business Development Sep 08, 2010 Tekmira Pharmaceuticals Strengthens Management Team with Addition of Paul Brennan as Senior Vice President, Business Development 17.8 KB ... Read more Summary ToggleTekmira Pharmaceuticals Receives Clearance from FDA to Initiate TKM-PLK1 Phase 1 Clinical Trial Sep 07, 2010 Tekmira Pharmaceuticals Receives Clearance from FDA to Initiate TKM-PLK1 Phase 1 Clinical Trial 18.5 KB ... Read more Summary ToggleTekmira Pharmaceuticals Announces Second Quarter 2010 Financial Results Aug 12, 2010 Tekmira Pharmaceuticals Announces Second Quarter 2010 Financial Results 30.4 KB ... Read more Summary ToggleTekmira Pharmaceuticals Conference Call Advisory Second Quarter 2010 Operating Results and Corporate Update Aug 10, 2010 ... Read more Summary ToggleTekmira Pharmaceuticals Files IND Application with U.S. FDA for PLK1 SNALP Aug 05, 2010 Tekmira Pharmaceuticals Files IND Application with U.S. FDA for PLK1 SNALP 18 KB Clinical Trial for RNAi Cancer Program on Track to Commence in Second Half of 2010 ... Read more Summary ToggleTekmira Awarded up to $140 Million U.S. Government Contract to Develop RNAi Therapeutic Against Ebola Virus Jul 15, 2010 Tekmira Awarded up to $140 Million U.S. Government Contract to Develop RNAi Therapeutic Against Ebola Virus 20.3 KB ... Read more Summary ToggleTekmira’s Partner Alnylam Initiates Dosing in a Phase 1 Clinical Trial of ALN-TTR01 Jul 07, 2010 Tekmira’s Partner Alnylam Initiates Dosing in a Phase 1 Clinical Trial of ALN-TTR01 19.9 KB -ALN-TTR01 Utilizes Tekmira’s Leading SNALP Delivery Technology- ... Read more Summary ToggleTekmira Partner Alnylam Presents ALN-VSP Preliminary Phase 1 Clinical Trial Results at American Society of Clinical Oncology (ASCO) Annual Meeting Jun 07, 2010 Tekmira Partner Alnylam Presents ALN-VSP Preliminary Phase 1 Clinical Trial Results at American Society of Clinical Oncology (ASCO) Annual Meeting 18.8 KB ... Read more Summary ToggleTekmira Reports Complete Protection from Deadly Ebola Virus in Nonhuman Primates with SNALP-RNAi May 28, 2010 Tekmira Reports Complete Protection from Deadly Ebola Virus in Nonhuman Primates with SNALP-RNAi 22.2 KB <ul><li>Data Reflects High Potency and Utility of RNAi in Infectious Disease Applications</li></ul> ... Read more Pagination First page First Previous page Previous … Page 43 Current page 44 Page 45 Page 46 … Next page Next Last page Last
Tekmira Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference and the Stifel Nicolaus Healthcare Conference 13.7 KB
Tekmira Pharmaceuticals Strengthens Management Team with Addition of Paul Brennan as Senior Vice President, Business Development 17.8 KB
Tekmira Pharmaceuticals Receives Clearance from FDA to Initiate TKM-PLK1 Phase 1 Clinical Trial 18.5 KB
Tekmira Awarded up to $140 Million U.S. Government Contract to Develop RNAi Therapeutic Against Ebola Virus 20.3 KB
Tekmira Partner Alnylam Presents ALN-VSP Preliminary Phase 1 Clinical Trial Results at American Society of Clinical Oncology (ASCO) Annual Meeting 18.8 KB
Tekmira Reports Complete Protection from Deadly Ebola Virus in Nonhuman Primates with SNALP-RNAi 22.2 KB